An Introduction to the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study
Samuel S. Gidding MD and Richard Vander Heide MD, PhD, MBA
In the mid-1980s, three pioneers of atherosclerosis pathologic research, Robert Wissler MD, Jack Strong MD, and Henry McGill MD initiated the PDAY study. The founding idea was that atherosclerosis developed over the life span of an individual and if the process could be arrested or delayed early in life, the epidemic of acquired cardiovascular disease could be prevented. Essentially, they wanted to build on the observation that atherosclerosis had been identified in the young casualties of the Korean and Viet Nam conflicts by demonstrating the relationship of early atherosclerosis to established risk factors which included elevated serum lipid levels, hypertension, diabetes, smoking, and obesity. The principals all had experience with primate models where all of these risk factors were confirmed to cause atherosclerosis. Read more

• 2012 David Kritchevsky Memorial Lecture on “Starting Earlier to Prevent Heart Disease” delivered by McGill Henry
• Lecture on “Pathology of Atherosclerosis in Childhood” delivered by McGill Henry
• PDAY Study Bibliography

ScreenPro - Screening Project for Familial Hypercholesterolemia in Central, Southern, and Eastern Europe

Severe FH Course “Identifying and Treating Severe Familial Hypercholesterolemia” (Dubai, UAE, October 14-15, 2017)

IAS Consensus Statement “Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel”
The International Atherosclerosis Society (IAS) is proud to announce the publication on the definition of severe FH and the implications for clinical management in The Lancet Diabetes and Endocrinology.

The IAS Nominating Committee, chaired by Philip Barter (Australia) and composed by Anne Goldberg (USA), Chris Packard (UK), and Brian Tomlinson (Hong Kong), has presented the IAS Council the final slate of the candidates to be elected during the ISA2018 congress in Toronto. The Council of the Constituent Societies has elected the future Board members during its meeting on June 11, 2018.

We are thrilled to announce the new Executive Board which will begin its term on January 1, 2019 and will serve until December 31, 2021. Read more

Welcome to our new Member Societies !

Iraqi Lipid Clinics Network

Kuwait 5000

Saudi Group for Cardiovascular Prevention and Rehabilitation

The Antonio M. Gotto, Jr. Prize in Atherosclerosis Research was awarded to Dr. Daniel J. Rader, an investigator from the Perelman School of Medicine, during the XVIII International Symposium on Atherosclerosis held on June 9-12 in Toronto, Canada.
The triennial Prize, endowed by Weill Cornell Medicine and the International Atherosclerosis Society in honor of Dr. Gotto, Dean Emeritus of Weill Cornell Medicine, recognizes outstanding scientific, medical or organizational advancement in our ability to understand the causes and the development of atherosclerosis.
The award was made in recognition of Daniel’s as a leading translational scientist who has made major contributions to our understanding of lipoprotein metabolism. His work is distinguished by its clear and direct impact on the development of new therapeutic strategies to prevent coronary heart disease (CHD). Rader discovered endothelial lipase and elucidated its role in metabolism of high density lipoproteins (HDL). He developed novel methods to trace macrophage-specific RCT in mice and assess HDL function in humans. Rader also singlehandedly championed microsomal triglyceride transfer protein (MTP) inhibitors for treatment of severe hypercholesterolemia. Rader has provided important new insights into the mechanisms by which common sequence variations discovered in genome-wide association studies alter plasma lipoprotein levels. His work spans the full spectrum of translational research, extending from basic laboratory science to the development and testing of new therapeutic agents in humans. His work has had a major impact on current strategies to prevent and treat CHD.

• Press Release on the Penn Med News site: https://www.pennmedicine.org/news/news-releases/2018/june/penn-medicine-geneticist-receives-2018-gotto-prize-from-international-atherosclerosis-society
• Press Release from Weill Cornell Medicine website: https://news.weill.cornell.edu/news/2018/06/antonio-m-gotto-jr-prize-in-atherosclerosis-research-awarded
• Photos of the Ceremony of the Gotto Prize

We are pleased to announce that after the presentation of the outstanding bids for the ISA2024 Symposium from the Russian National Atherosclerosis Society (RNAS), Emirates Cardiac Society (ECS), Lipid Association of India (LAI), and Oman Society of Lipids & Atherosclerosis (OSLA) the IAS Executive Board during its meeting held in Toronto on June 9 has selected the winner of the ISA2024: the Oman Society of Lipids and Atherosclerosis (OSLA).

The International Atherosclerosis Society (IAS) and Oman Society of Lipid & Atherosclerosis (OSLA) are organizing the Fifth IAS-OSLA Course "Lipid Metabolism and Cardiovascular Risk" to be held in Muscat, Oman, on February 8-12, 2019.
As in 2015, 2016, 2017 and 2018, the aim of this Course is to increase the knowledge and experience of early- to mid-career, English-speaking practicing clinicians interested in the management of lipid disorders and will be restricted to 30 clinicians from the Middle East and North Africa (MENA) region who manage patients with lipid disorders.

Who can apply: Clinicians (including adult or pediatric cardiologists, endocrinologists, general practitioners, lipidologists, clinical biochemists) below the age of 40 years who are currently working at a hospital/university/other health institute in the MENA region.

More information will follow.